Doctor profile · Federal record
Dr. Merla Puray, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Merced, CA
- NPI 1952314205
- Accepts Medicare
- MIPS 100.0 / 100 · 2023
- 32 yrs in practice
- Female
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
3175 Collins Dr
Merced, CA 953483133
(209) 722-5100
fax (209) 722-5200
Credentials & registration
- NPI registered
- August 2006 — 20 yrs on file
- Profile last updated
- August 29, 2014
- Year of graduation
- 1994 — 32 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- California #A98668
- Medicaid
- CA #00A986680
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1952314205. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
78,177
Distinct HCPCS
10
Medicare allowed
$881,672
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 52,020 | 41 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 15,960 | 117 | $23 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 1,924 | 598 | $132 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 1,776 | 23 | $0 | |
J2469 |
Injection, palonosetron hcl, 25 mcg | 1,240 | 21 | $1 | |
J2405 |
Injection, ondansetron hydrochloride, per 1 mg | 1,064 | 17 | $0 | |
J3489 |
Injection, zoledronic acid, 1 mg | 663 | 87 | $9 | |
Q5122 |
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 576 | 11 | $113 | |
96372 |
Injection of drug or substance under skin or into muscle | 508 | 145 | $15 | |
96367 |
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 396 | 36 | $30 |
In context: peer comparison
Among 2 peers in this city , average services per provider: 2,624. This provider delivers 30× the peer median.Open Payments
Industry payments received
All-time total
$1,436
Transactions
47
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 11 | $160.13 | |
| AstraZeneca Pharmaceuticals LP | 3 | $142.05 | |
| Astellas Pharma US Inc | 3 | $132.67 | |
| Aveo Pharmaceuticals, Inc. | 2 | $126.24 | |
| Merck Sharp & Dohme LLC | 5 | $123.81 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $73.64 | |
| Gilead Sciences, Inc. | 4 | $72.35 | |
| Mirati Therapeutics, Inc. | 3 | $71.11 | |
| GENZYME CORPORATION | 2 | $59.16 | |
| Exelixis Inc. | 2 | $58.52 | |
| E.R. Squibb & Sons, L.L.C. | 2 | $57.88 | |
| Eisai Inc. | 2 | $57.61 | |
| Daiichi Sankyo Inc. | 2 | $48.95 | |
| SOBI, INC | 2 | $46.91 | |
| ADC Therapeutics America, Inc. | 1 | $33.73 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
400
Patients
32
Total drug cost
$1,973,269
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Jakafi (Ruxolitinib Phosphate) | Brand | 62 | 0 | $1,175,012 |
| Anastrozole | Generic | 57 | 18 | $1,782 |
| Letrozole | Generic | 46 | 14 | $2,166 |
| Exemestane | Generic | 42 | 0 | $14,307 |
| Lenalidomide | Generic | 28 | 0 | $350,743 |
| Hydroxyurea | Generic | 25 | 0 | $989 |
| Prednisone | Generic | 23 | 0 | $314 |
| Revlimid (Lenalidomide) | Brand | 22 | 0 | $415,191 |
| Potassium Chloride | Generic | 18 | 0 | $1,416 |
| Deferasirox | Generic | 14 | 0 | $10,171 |
Frequently asked questions
What is Dr. Merla Puray's medical specialty?
Dr. Merla Puray practices Hematology & Oncology Physician in Merced, CA.
Where does Dr. Merla Puray practice?
Dr. Merla Puray practices at 3175 Collins Dr, Merced, CA 953483133. Office phone: 2097225100.
What is Dr. Merla Puray's NPI?
Dr. Merla Puray's National Provider Identifier (NPI) is 1952314205, issued by NPPES.
Does Dr. Merla Puray accept Medicare assignment?
Yes. Dr. Merla Puray accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Merla Puray commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, denosumab, 1 mg (HCPCS J0897); Established patient office or other outpatient visit (HCPCS 99214). Source: CMS Medicare Physician & Other Practitioners file.